The U.S. Food and Drug Administration has granted accelerated approval for the first-ever gene therapy, Elevidys, targeting Duchenne Muscular Dystrophy.
This groundbreaking development has been facilitated by research conducted in Rochester, and the therapy underwent phase three of its clinical trial at the University of Rochester Medical Center (URMC).
The approval will benefit pediatric patients aged four and five diagnosed with DMD, a debilitating condition that primarily affects boys, often leading to loss of mobility by their teenage years.
This gene therapy aims to replace the faulty gene responsible for the disease, marking a significant advancement from traditional symptomatic treatments.
Notably, participating families have reported significant improvements post-infusion.
Clinical trials continue as the makers of Elevidys work toward securing full approval for the therapy for children up to seven years old.
Make FL1 part of your day.
Local reporting. Useful updates. More ways to stay close to your community.
Go ad-free
Support independent local reporting and enjoy FL1 without display ads.
$4.99 / month
Become a member →Cancel anytime. Third-party media players may contain ads.Get the daily briefing
Start your morning with the headlines that matter across the Finger Lakes.
Find more FL1 on Google
Choose FingerLakes1.com as a preferred source to see more of our reporting in your Google news results.





